|  |  |
| --- | --- |
| Fourth floorThe Counting House53 Tooley StreetLondon SE1 2QN | Telephone 020 3310 7000Fax 020 3310 7107info@prostatecanceruk.org**prostatecanceruk.org** |



**This template can be used to assist with completing the online application form. It cannot be submitted as an application to Prostate Cancer UK. Applications must be submitted online through our** [**CC Grant Tracker system**](https://grants.prostatecanceruk.org/Login.aspx?ReturnUrl=%2f)

Application Form

|  |  |
| --- | --- |
| **Grant Type** |  |
| **Grant Round**  |  |
| **Reference Number**  |  |
| **Lead Applicants**  |  |
| **Host Institution**  |  |
| **Research Title** |  |
| **Total Research Cost** |  |
| **Duration (months)**  |  |

|  |
| --- |
| **Abstract**  |
| *Pulled from ’Proposal Summary section’* |

### **Introduction**

**\*\*We strongly advise you to download and read the accompanying** [**Guidance Notes**](https://prostatecanceruk.org/media/ctjfo1gd/transformational-impact-awards-23-24-guidance.pdf) **and** [**Finance Guidance**](https://prostatecanceruk.org/research/for-researchers/our-funding-process-and-how-to-apply/finance-guidance) **which will assist you with the completion of this application form\*\***

##  Remit & Eligibility

Our Transformational Impact Awards support large-scale research investments covering high-quality discovery science, through to translational and clinical research. These awards will deliver research which cannot be achieved through our other funding schemes (namely our [Research Innovation Awards](https://prostatecanceruk.org/research/for-researchers/funding-opportunities/research-innovation-awards)), with the ambition to significantly expand our understanding of the disease, maximise the scale and speed of progress in prostate cancer research and crucially deliver a positive impact on the lives of men with prostate cancer. This may be by:

* directly delivering evidence that leads to practice change and patient benefit;
* significantly accelerating the progression towards that patient benefit;
* delivering a transformational step change in our understanding of the disease

This scheme is designed to support individual clinical studies, as well as programmes of research (preclinical, clinical or a combination) consisting of highly interconnected workstreams, that offer added benefit when delivered collectively. All proposals must be in line with our [Research Strategy](https://prostatecanceruk.org/research/our-research-strategy) and be focussed towards tackling one or more of the research themes set out in the accompanying guidance notes.

**All applications must be submitted by the Lead Applicant and approved by the Head of Department and Finance Officer before the round closes at 1pm on 14 September 2023. We suggest that you allow at least 5 working days to ensure that all relevant parties submit their approvals in advance of the submission deadline.**

# **Budget**

* We anticipate that proposals will be around £1.5m in value and up to 5 years in duration. Proposals up to the value of £2m will still be accepted, however, if you wish to apply for more than £1.5m, you must discuss your study with us in advance of the submission deadline.
* Proposals under £750k are likely to be better suited to our [Research Innovation Awards](https://prostatecanceruk.org/research/for-researchers/funding-opportunities/research-innovation-awards) scheme.
* Value for money will be a consideration in our funding decisions, and the requested budget must be a realistic reflection of what is required to deliver the proposed research. Budgets must be in accordance with our [Finance Guidelines](https://prostatecanceruk.org/research/for-researchers/our-funding-process-and-how-to-apply/finance-guidance), and where applicable in line with the [AcoRD framework](https://www.gov.uk/government/publications/guidance-on-attributing-the-costs-of-health-and-social-care-research) for attributing the costs of clinical research.
* We anticipate having a sufficient budget for this scheme to support 2-3 proposals each year.

# **Study Leadership**

* Proposals must be led by a designated Lead Applicant who is an established researcher with a strong track record in their field, and who holds a tenured or tenure-track academic appointment, or for clinical applicants they should hold an honorary academic contract, at a recognised academic institution in the UK.
* Up to 4 additional ‘senior’ Joint Lead Applicants can also be named on the proposal, where each person will play an active role in the management and delivery of the proposed study. These individuals can be based in the UK or internationally.
* We are very much open to bringing new expertise and ideas into the prostate cancer field, and academics not currently working on prostate cancer are welcome to apply to this scheme (in such cases we would however strongly recommend that an expert from the prostate cancer research community is also named as a Joint Lead Applicant on the proposal).

# **Career Development & Support**

* Proposals must include (at least) one experienced Early Career Researcher as a named Joint Lead Applicant on the proposal, who will play an active role in the delivery of the programme/study and who will be responsible for a particular element(s) of it (NB/ this is in addition to the 4 ‘senior’ Joint Lead Applicants mentioned above). We define an experienced Early Career Researcher as someone who has between 5-10 years post-doctoral experience if a non-clinical researcher, or up to 5 years post-doctoral experience if a clinical researcher.
* If it is not already covered through other means, their salary may be included in the application budget up until the end of the grant, as long as the salary requested is proportionate to the amount of time they will be spending on the grant. The purpose of this is to support the individual in their career progression in order for them to achieve independence by the end of the grant (including securing long-term salary support outside of this grant, either through a tenured position or a substantial fellowship award). We would expect to see the input of this individual reflected in the scientific outputs from the grant and we also want to see commitment from the host institution towards the mentorship, training and support for this individual in their career development. The support and career development plan proposed to move this individual towards an independent leadership role in prostate cancer will be key consideration when assessing your proposal.
* We are keen to see these awards also provide training and development opportunities for additional early career researchers. Where it supports the delivery of the proposed research, we encourage the inclusion of PhD Studentships or Clinical Fellows working towards a PhD qualification. Again, we would expect to see appropriate commitment from the host or collaborating institution to provide suitable mentorship, training and support for these individuals.

#

# **Partnerships & Collaboration**

* In all but exceptional circumstances we would expect proposals to be multi-institutional to facilitate and encourage collaboration, and where appropriate we strongly encourage international and/or industry collaboration. We also welcome submissions which bring in new ideas and expertise from other research fields/disciplines. You should consider not only the necessary fields of expertise required for the proposal, but also the diversity and make up of the applicant team. Please note that studies must be led by a UK-based researcher from a UK research institution (and it will then be the responsibility of the host institution to arrange sub-contracts and distribution of funds to the collaborating parties, both within the UK and internationally).
* Proposals which can demonstrate additional leveraged support from the host institution and/or from collaborating partners will be looked upon favourably. Applicants should therefore consider what upfront leveraged support might be available from other sources to provide added benefit to the focus of this proposal, as well as what their strategy will be for gaining further additional leveraged support if this application was successful.

**Please note that we will NOT accept applications that:**

* Do not fit our Research Strategy or which do not address any of the research themes within this scheme.
* Are intended solely or primarily to purchase substantial equipment. This scheme is aimed to support hypothesis-driven research. Proposals that are not sufficiently hypothesis-driven are likely to be rejected in all but exceptional circumstances;
* Are only focussed on supporting the development/maintenance of research infrastructure and/or resources (such as biorepositories, databases etc.). Whilst it is permissible to include a proportion of the grant funds to support such infrastructure/resource, this must not be the sole (or primary) focus of the proposal. In this instance, we expect to see the utilisation of these resources to address hypothesis-led research questions. Ultimately, to meet the “transformational” remit of this funding scheme, such proposals must offer significant additional scientific merit over and above just maintaining the resource/infrastructure and must have clearly defined deliverables by the end of the programme;
* Are led and submitted by researchers based entirely or primarily outside the UK
* Are submitted by commercial organisations
* Are incomplete or have been completed incorrectly

## Assessment Process

**14 September 2023 (1pm): Deadline for application submission**

**w/c 27 November 2023:** Applicants invited to submit a rebuttal to peer reviewer comments

**11 December 2023 (1pm):** Deadline for rebuttal submission

**Mid-January 2024:** Applicants shortlisted for interview

**19 and 23 February 2024:** Shortlisted applicants interviewed by our Scientific Advisory Board via video conference

**March 2024: Applicants notified of their outcome**

*We recognise that the outcome of your application is important to you and we will inform you of the outcome as soon as possible. We appreciate your patience during this time.*

## Contact us

If you are unsure about the eligibility of your proposal, or if you have any queries about completing the application form, you must contact us**in advance** of the submission deadline (email: ).  Once the deadline has passed, you will no longer be able to submit your proposal and there will be no opportunity to debate individual circumstances. Applications which are incomplete, which do not meet the requirements detailed above and which are deemed to be outside of our [research strategy](http://prostatecanceruk.org/research/our-research-strategy) will be rejected without being sent for further review.

|  |
| --- |
| **Lead Applicant Details** |

Some of the information in this section is automatically populated from your contact record and will be read only.  Please ensure that your Employment, Education and Basic Information are up to date via the 'Manage My Details' section.

**ORCID ID** - All applicants must have an up to date [ORCID](http://orcid.org/) account and the ORCID ID must be added to the corresponding section under 'Basic Information' via 'Manage My Details'. Please ensure that you have populated your ORCID record and set visibility to ‘public’. For more details, please visit the ORCID website.

|  |  |
| --- | --- |
| **Full Name** | *(Auto populated….)* |
| **Position** | *(Auto populated….)* |
| **Department**  | *(Auto populated….)* |
| **Institution**  | *(Auto populated….)* |
| **ORCID iD**  | *(Auto populated….)* |

**Education**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **From** | **To**  | **Qualification**  | **Subject**  | **Country**  | **Institution**  | **Class** | **Department** |
| *(Auto populated from the ‘Manage my details’ section)* | *(Auto populated….)* | *(Auto populated….)* | *(Auto populated….)* | *(Auto populated….)* | *(Auto populated….)* | *(Auto populated….)* | *(Auto populated….)* |

**Employment**

|  |  |  |  |
| --- | --- | --- | --- |
| **From** | **To**  | **Position** | **Organisation**  |
| *(Auto populated from the ‘Manage my details’ section)* | *(Auto populated….)* | *(Auto populated….)* | *(Auto populated….)* |

|  |
| --- |
| **Publications*** Examples of Vancouver formatted references:

*Endres M, Engelhardt B, Koistinaho J, Lindvall O, Meairs S, Mohr JP, et al. Improving outcome after stroke: Overcoming the translational roadblock. Cerebrovasc Dis. 2008, Feb, 22;25(3):268-78.**Fanta CH. Asthma. N Engl J Med. [Internet] 2009 [cited 2013 Jan 9]; 360(10):1002-14. Available from: doi: 10.1056/NEJMra0804579**Foley KM, Gelband H, editors. Improving palliative care for cancer [Internet]. Washington: National Academy Press; 2001 [cited 2002 Jul 9]. Available from: https://www.nap.edu/catalog/10149/improving-palliative-care-for-cancer**Harnden P, Joffe JK, Jones WG, editors. Germ cell tumours V. Proceedings of the 5th Germ Cell Tumour Conference; 2001 Sep 13-15; Leeds, UK. New York: Springer; 2002.*Please enter up to 10 of your most significant/relevant publications for this application. Publications should be entered in Vancouver format. |
| Mandatory |

|  |
| --- |
| **Grants**Please enter up to 10 of your most significant/relevant grants for this application.*For each entry, please ensure you include your role (e.g. Lead applicant),* *the grant reference, the name of the funding organisation, the amount awarded, the title of the project, and the project start and end dates).* |
| Mandatory |

|  |
| --- |
| **FTE %**How much time will you be contributing towards the proposed study? (Please include as full time equivalent) |
| Mandatory |

|  |
| --- |
| **Lead Applicant Role**Please describe your role on the proposed study. |
| Mandatory*max. 200 words* |

**Narrative CV – Evidencing your contributions to the field**
This section is designed to help you capture your achievements, skills and contributions to the research sector (aside from grants and publications) that are of particular relevance to this application. Please ensure you highlight your specific contribution when giving examples so that reviewers can clearly understand the role you have played in advancing our understanding of prostate cancer and in supporting the wider research community.

|  |
| --- |
| **How have you contributed to the generation of knowledge?** Highlight how you have contributed to the generation of new ideas, tools or techniques. Please describe what you have discovered/developed, your specific contribution to it, why it is important and what its impact and influence have been in your field. *Please also consider research outputs beyond purely publications and grants, such as delivery of clinical trials, contribution to consortia, awards you have received, patents, open datasets, software, novel assays, reagents etc.*  |
| Mandatory*max. 500 words* |

|  |
| --- |
| **How have you contributed to the development of others?** Please highlight how you have supported others in the field and where your experience and expertise has been critical to the success of others, either within a team, part of a collaboration, or through mentorship**.** *Examples: Teaching activities, involvement in workshops or summer schools, supervision, mentoring, strategic leadership, involvement in establishing collaborations etc*. |
| Mandatory*max. 500 words* |

|  |
| --- |
| **How have you contributed to the wider research community?**Describe your contributions and engagement with the local and international research community. *Examples: editing, reviewing, refereeing, committee membership and your contributions to the evaluation of researchers and research projects. The organisation of conferences/events and how they benefitted the research community. Any contributions to improving research culture (research integrity, equality, diversity and inclusion, mobility of researchers, reward and recognition of researchers' various activities), and appointments to positions of responsibility within your department/institution or other organisations* |
| Mandatory*max. 500 words* |

|  |
| --- |
| **How have you contributed towards broader society (in a research capacity)?**Please highlight any examples of societal engagement and knowledge exchange in relation to your research.*Examples may include any outreach/STEM activities in schools, engagement with the public sector or the broader public, and/or with industry. You may wish to highlight positive stakeholder feedback, inclusion of patients in your research, or collaboration and engagement with particular societal or patient groups. You could also use this section to mention any occasions where you’ve provided advice to policy-makers at local, national or international level, experience of communication and information dissemination through media/press/social media, and any other impact across research, policy, practice and business.* |
| Mandatory*max. 500 words* |

|  |
| --- |
| **Personnel** |

**Joint-Lead Applicant(s)**

Up to 4 additional ‘senior’ Joint Lead Applicants can also be named on the proposal, where each person will play an active role in the management and delivery of the proposed study. These individuals can be based in the UK or internationally.

Proposals must include (at least) one experienced Early Career Researcher as a named Joint Lead Applicant on the proposal, who will play an active role in the delivery of the programme/study and who will be responsible for a particular element(s) of it (NB/ this is in addition to the 4 ‘senior’ Joint Lead Applicants mentioned above). We define an experienced Early Career Researcher as someone who has between 5-10 years post-doctoral experience if a non-clinical researcher, or up to 5 years post-doctoral experience if a clinical researcher.

 To invite a Joint-Lead Applicant, click below and use the search fields to lookup their contact record. Alternatively, you can 'Add a New Contact' and enter their details.

**All Joint-Lead Applicants must confirm their participation AND approve the application BEFORE the proposal can be ‘submitted’**.

Add Joint-Lead Applicant...

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Joint-Lead Applicant** | **CV** | **Organisation** | **Status** | **FTE %** | **Joint-Lead Applicant Role** | **Joint-Lead Applicant Personal Statement** | **Joint-Lead Applicant contributions** |

**Selecting ‘Add Joint-Lead Applicant’ pop up window:**

Use the fields below to search for a contact.

|  |  |
| --- | --- |
| First Name |  |
| Last Name |  Mandatory Field |

**Joint-Lead Applicant CV Questions**

You may complete the questions below later. Clicking ‘Save’ will invite the Joint-Lead Applicant and save any information you have entered.

|  |
| --- |
| **Publications**Please enter up to 10 of your most significant/relevant publications for this application. Publications should be entered in Vancouver format. |
| Mandatory |

|  |
| --- |
| **Grants**Please enter up to 10 of your most significant/relevant grants for this application.*For each entry, please ensure you include your role (e.g. Lead applicant),* *the grant reference, the name of the funding organisation, the amount awarded, the title of the project, and the project start and end dates.* |
| Mandatory |

**Narrative CV – Evidencing your contributions to the field**
This section is designed to help you capture your achievements, skills and contributions to the research sector (aside from grants and publications) that are of particular relevance to this application. Please ensure you highlight your specific contribution when giving examples so that reviewers can clearly understand the role you have played in advancing our understanding of prostate cancer and in supporting the wider research community.

|  |
| --- |
| **How have you contributed to the generation of knowledge?** Highlight how you have contributed to the generation of new ideas, tools or techniques. Please describe what you have discovered/developed, your specific contribution to it, why it is important and what its impact and influence have been in your field. *Please also consider research outputs beyond purely publications and grants, such as delivery of clinical trials, contribution to consortia, awards you have received, patents, open datasets, software, novel assays, reagents etc.* |
| Mandatory*max. 500 words* |

|  |
| --- |
| **How have you contributed to the development of others?** Highlight any expertise you have provided which has been critical to the success of others, either within a team, part of a collaboration, or through mentorship**.** *Examples: Teaching activities, involvement in workshops or summer schools, supervision, mentoring, strategic leadership, and/or involvement in establishing collaborations etc.* |
| Mandatory*max. 500 words* |

|  |
| --- |
| **How have you contributed to the wider research community?**Please highlight any examples of societal engagement and knowledge exchange in relation to your research.*Examples: editing, reviewing, refereeing, committee membership and your contributions to the evaluation of researchers and research projects. The organisation of conferences/events and how they benefitted the research community. Any contributions to improving research culture (research integrity, equality, diversity and inclusion, mobility of researchers, reward and recognition of researchers' various activities), and appointments to positions of responsibility within your department/institution or other organisations.* |
| Mandatory*max. 500 words* |

|  |
| --- |
| **How have you contributed towards broader society (in a research capacity)?**Please highlight any examples of societal engagement and knowledge exchange in relation to your research*Examples may include any outreach/STEM activities in schools, engagement with the public sector or the broader public, and/or with industry. You may wish to highlight positive stakeholder feedback, inclusion of patients in your research, or collaboration and engagement with particular societal or patient groups. You could also use this section to mention any occasions where you’ve provided advice to policy-makers at local, national or international level, experience of communication and information dissemination through media/press/social media, and any other impact across research, policy, practice and business.* |
| Mandatory*max. 500 words* |

**Joint-Lead Applicant(s) Role & FTE**

**Please use this section to enter details of the Role & FTE % for Joint-Lead Applicant(s) on the proposed study**.

Add Joint-Lead Applicant Role & FTE %...

|  |  |  |
| --- | --- | --- |
| **Joint-Lead Applicant** | **FTE %** | **Joint-Lead Applicant Role** |

**Selecting ‘Add Joint-Lead Applicant Role & FTE %…’ pop up window:**

|  |  |
| --- | --- |
| **FTE%**How much time will this person be contributing towards the proposed study? (please include as full time equivalent) | Mandatory Field |

|  |
| --- |
| **Joint-Lead Applicant Role**Please provide further details regarding the role this person shall undertake. In the instance of Joint-Lead Applicants, please clarify which aspects of the proposal each person will be leading on and why they are appropriate to lead on that aspect of the project. Proposals must include (at least) one experienced Early Career Researcher as a Joint Lead Applicant and you should justify why they are suitable for this role. |
| Mandatory*max. 200 words* |

|  |
| --- |
|  |

**Co-Applicant(s)**

'Please add all Co-Applicants on your proposal via the 'Add Co-Applicant…' button below.'

You must describe the role of EACH Co-Applicant.

**All Co-Applicant(s) must confirm their participation AND approve the application BEFORE the proposal can be ‘submitted’**.

Add Co-Applicant...

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Co-Applicant**  | **Organisation** | **Status** | **%FTE** | **Co-Applicant Role** |  |
|  |  |  |  |  | Edit…Delete… |

**Selecting ‘Add Co-applicant’ pop up window:**

Use the fields below to search for a contact.

All Co-Applicants must have an active role in the proposal. Any other personnel should be listed as a Collaborator.

|  |  |
| --- | --- |
| First Name |  |
| Last Name |  Mandatory Field |

|  |  |
| --- | --- |
| **FTE%**How much time will this person be contributing towards the proposed study? (please include as full time equivalent) | Mandatory Field |

|  |
| --- |
| **Co-Applicant Role**Please provide further details regarding the role this person shall undertake. |
| Mandatory*max. 200 words* |

|  |
| --- |
|  |

**Collaborator(s)**

Please add all Collaborators on your proposal via the 'Add Collaborator…' button below.

We no longer require letters of support from all of your collaborators, but instead they are required to confirm their participation before submission. However, you may include any letters of support from your collaborators where you think it will provide crucial additional details regarding their involvement in the study, which has not already been described elsewhere in your proposal (e.g. where delivery is fundamentally dependant on access to patient samples/datasets)

**All Collaborator(s) must confirm their participation BEFORE the proposal can be ‘submitted’**.

Add Contact

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Name** | **Organisation** | **Status** | **Collaborator Role** | **Collaborator Letter** |  |
|  |  | Notified of Participation |  |  | Remove |

**Selecting ‘Add Collaborator’ pop up window:**

|  |  |
| --- | --- |
| First Name |  |
| Last Name |  Mandatory Field |

|  |
| --- |
| **Collaborator Role** |
| Mandatory*max. 200 words* |

Collaborator Letter - Attach Optional
We no longer require letters of support from all of your collaborators, but instead they are required to confirm their participation before submission. However, you may include any letters of support from your collaborators where you think it will provide crucial additional details regarding their involvement in the study, which has not already been described elsewhere in your proposal (e.g. where delivery is fundamentally dependant on access to patient samples/datasets).

|  |
| --- |
| **Additional Team Information** |
| **Please detail how your team of investigators is best placed to deliver the proposed study?** Explain here why this team is most suited and well positioned to conduct this work. You should highlight how you have forged national/international collaborations to support this work and how you have brought together the necessary expertise within the research community (from within the prostate cancer field and/or from other disease areas) in order to work collaboratively to drive the field forward.You should consider not only the necessary fields of expertise required for the proposal, but also the diversity and make up of the applicant team. |
| Mandatory*max. 500 words* |

|  |
| --- |
| **How will this proposal provide opportunities for career development, support and training?**Proposals with a clear plan to provide training, support and career development opportunities will be looked upon favourably. Please describe how you will support the named Early Career Researcher(s) throughout the study and how this funding will produce demonstrable outputs that will significantly contribute towards their career progression. Please also outline your plans to embed and support other early career researchers through this proposal, for instance, the inclusion of PhD posts or training and development opportunities for early career post-doc researchers etc.*Note: We’re looking specifically for information on career support that will be provided directly throughout the duration of this grant (if awarded).* |
| MandatoryMax. 500 words |

|  |
| --- |
| **Additional information of relevance to the review of your application**Please use this section if you wish to highlight details of any significant breaks or reduction in activity in the research careers of the Lead and/or Joint-Lead Applicants. You may also use this section to highlight any other issues related to your application including any accessibility needs or reasonable adjustments (for the Lead and/or Joint-Lead Applicants) which may be required should this application be shortlisted for (a virtual) interview. If there's any information that you would prefer to share in confidence, please email research@prostatecanceruk.org *Note: The details in this section will be taken into consideration by our reviewers when assessing an individual's track record, outputs and career progression.* |
| Optional*max. 500 words* |

|  |
| --- |
| **Proposal Summary** |

|  |  |
| --- | --- |
| **Scientific title** |  |

|  |
| --- |
| **Duration (months)**A picture containing porcelain  Description automatically generatedIt is our expectation to see proposals in the region of £1.5m over 5 years in duration. Proposals shorter or longer than this are still eligible, but must be sufficiently justified. |
| X monthsMandatory |

|  |
| --- |
| **Proposed Start Date**(Cannot be before 01/04/2024) |
| Mandatory |

|  |
| --- |
| **Which of our strategic areas does this proposal predominantly seek to address?** Indicate which of Prostate Cancer UK’s priority areas your proposal predominantly sits within . See our [Research Strategy](https://prostatecanceruk.org/research/our-research-strategy) for more details. |
| Better Diagnosis, Better Treatment, Smarter Use of Data Mandatory |

|  |
| --- |
| **Which Transformational Impact Award Research Theme does your proposal predominantly seek to address?** Please select only one (you may elaborate in the next question if the proposed study covers more than one theme). |
| * Translating novel diagnostic approaches
* Understanding high-risk localised disease
* Treatments for localised disease
* Detecting & treating localised recurrence
* Biology of metastatic disease
* Preventing progression to a hormone resistant state
* Novel treatments for castrate resistant prostate cancer
* Treatment resistance in advanced disease

Mandatory |

|  |
| --- |
| **Please justify your selected Research theme** |
| Mandatory*max. 100 words* |

|  |
| --- |
| **Key words**Select up to 6 keywords. Click the + to expand |
| MandatoryClick to hide unselected keywords Active surveillance, Epidemiology, Genetics, Genomics, Hormone resistant, Hormone signalling, Hormone therapy, Hypoxia, Image-guided biopsy, Image-guided radiotherapy, Imaging, Advanced prostate cancer, Locally advanced prostate cancer, Metastasis, Molecular biology, Proteomics, PSA, Radiography, Radiotherapy, Risk stratification,Signalling pathways, Stem cells, Androgen signalling, Surgery, Survivorship, Therapeutics, Tumour detection,Tumour inhibition, Tumour regulation, Androgens, Biomarkers, Castration resistance, Chemotherapy, Diagnosis, Drug development  |

|  |
| --- |
| **Scientific Abstract**Briefly outline the proposal, including background and expected outcomes.**Please do not include any confidential or commercially sensitive information in this section.**A picture containing porcelain  Description automatically generated**Scientific Abstract**Please provide a brief description (in no more than 500 words) to outline the background to the application, the proposed aims/work-packages of the research to be undertaken and the expected outcomes.  All proposals must clearly state how the planned research aims to improve the health and wellbeing of men affected by, or at high risk of, prostate cancer.Please be aware that your abstract will be sent to potential peer reviewers to establish their ability to review the proposal, and if funded, the abstract will also be shared with partnering organisations including the Association of Medical Research Charities (AMRC), Movember, the National Cancer Research Institute (NCRI) and the International Cancer Research Partnership (ICRP).**Therefore, please do not include any confidential or commercially sensitive information in this section.** |
| Mandatory*max. 500 words* |

|  |
| --- |
| **Main aims**Briefly summarise the main aims of the proposal in no more than 200 words. |
| Mandatory*max. 200 words* |

|  |
| --- |
| **Key hypotheses, objectives and milestones**Please detail the main hypotheses to be investigated, setting out the key objectives of the proposal, broken down into work-packages where appropriate. Provide a short description of how each objective will be achieved and a brief timetable of milestones (in no more than 500 words). All proposals should articulate a strong, central research question/theme and be placed in the context of current knowledge and the potential benefit for men affected by prostate cancer. |
| Mandatory*max. 500 words* |

|  |
| --- |
| **Research Delivery** |

This scheme aims to support larger-scale research investments covering high quality discovery science, through to translational and clinical research. Proposals should have the ambition to significantly expand our understanding of the disease, maximise the scale and speed of progress in prostate cancer research and, crucially, deliver a positive impact on the lives of men with prostate cancer. This may be through directly delivering evidence that leads to practice change and patient benefit; or by significantly accelerating the progression towards that patient benefit; or by delivering a transformational step change in our understanding of the disease.

All proposals should articulate a strong, central research question/theme and be placed in the context of current knowledge and the potential benefit for men affected by prostate cancer.

|  |
| --- |
| **Background to the proposal**A picture containing porcelain  Description automatically generated **Background to the proposal**Introduce only the most relevant background information necessary to understand the wider context of your proposal – do not write a literature review.  You should describe both your own and others' results that provide a basis for doing this research now, and how this proposal will accelerate work in this area. Please also outline any ongoing work that may impact either positively or negatively on your proposed study.  Please also describe how the proposed research is timely, why it is now an opportune moment to perform this study and why larger-scale funding is now required to deliver this work.It is advised that you place your proposal into a patient-centred context rather than focussing on scientific questions alone.  Please refer to references by number in this section and list them in full under the ‘References’ section (a maximum of 200 references are permitted). |
| Mandatory*max. 2000 words* |

|  |
| --- |
| A picture containing porcelain  Description automatically generated**Preliminary data****Preliminary data**Please detail any preliminary/pilot data that supports your application, including the strengths and weaknesses (methodological or field-specific) in the rigour of the prior research (in no more than 2000 words). Figures can be included by uploading up to 3 MS Word or PDF documents via the 'Optional preliminary data figure attachments' section and following the on-screen prompts.  Papers that have been accepted for publication but are not yet in print can also be uploaded below if you wish for them to be seen by the reviewers (however, manuscripts under review or in preparation cannot be provided as additional information). |
| Mandatory*max. 2000 words* |

|  |
| --- |
| **Optional preliminary data attachments**Please note - up to 3 MS Word or PDF documents can be attached (each upload should not exceed 10MB in file size)Add attachments… |

|  |
| --- |
| **Detailed plan of investigation**A picture containing porcelain  Description automatically generated **Detailed plan of investigation**Describe the methodology you will use to address each hypothesis, along with the timescales for each section of the research. Where appropriate this should be broken down into work-packages, with details of who shall be leading/delivering each component of the proposal.If your proposal includes a clinical study/component, please also complete the 'Clinical Research' section to provide further details of this element of the proposal, including power calculations, patient recruitment strategy, sample collection etc. Please also ensure you include details of your planned statistical analyses, highlighting any statistical methods you will employ and your approach to the analysis.An additional attachment (MS Word or PDF files only) may also be uploaded in this section (no greater than 10MB in file size). |
| Mandatory*max. 3500 words* |

|  |
| --- |
| **Optional attachment** Please note- only word or pdf documents can be attached (the document must be no greater than 10MB in file size)Add attachment… |

|  |
| --- |
| **Potential problems and contingency plans**We understand that research does not always run entirely to plan.  Please highlight any potential problems/risks with the research outlined in this proposal and how they will be appropriately mitigated and managed. |
| Mandatory*max. 300 words* |

|  |
| --- |
| **Clinical Research** |

This section only applies to those proposals that include a clinical component such as recruiting people/patients, patient data analysis or collecting samples from people/patients.

|  |
| --- |
| **Does this proposal involve clinical research?**A picture containing porcelain  Description automatically generated**Does this proposal involve clinical research?**This section only applies to those proposals that include a clinical component and require the recruitment of patients, patient data analysis or collecting samples from people/patients. If this section does not apply to you, please select ‘no’ to this question and move on to the next section.If your proposal does include a clinical component, please respond ‘yes’ to this question and complete this section in full. |
| Select ‘YES’ or ‘NO’Mandatory |

If ‘No’ selected for ‘Does this project involve clinical research?’ following appears:

Please move on to the next section.

If ‘Yes’ selected following question appears:

**Excess Treatment & NHS Support Costs**

**\*IMPORTANT NOTE** **Please be aware that the process for completing SoECAT forms has recently changed.\***

If your planned project includes the recruitment of participants, you are required to complete the Schedule of Events Cost Attribution Tool (SoECAT). This tool provides a standardised approach for attributing the costs of health and social care research and development (AcoRD) across England. Your application should be accompanied with the Funder Export from the online SoECAT, obtainable via the NIHR [Central Portfolio Management System (CPMS)](https://id.nihr.ac.uk/authenticationendpoint/login.do?RelayState=ss%3Amem%3A1cbf94314d0ea0ef984df1e00ea2b6acf662c131a8e9a9c5aebd4f9fd98c0098&SigAlg=http%3A%2F%2Fwww.w3.org%2F2001%2F04%2Fxmldsig-more%23rsa-sha256&Signature=yL9fAs4JtPkRmajzRqdC8iCuUjjHu8HUtCoNpEyv38ULfbXDkewL8mXCV4tqaVRyePoCckgYWN6eKvUn9Nvo0Z4qGBXDbgRDBRKozqjdr3Vl9lC7gyCsYUGi1wfE1P0mxAcP%2BLWQCCXVwymr6wSm%2FVUIVA4zRwWKy5nGznG7jvEsmOwPuYzGRvmFY6SIOEPu%2B2i9KwSJDD6QXg0pBhtcRUWSjEPvG2FFBNguNAIEVS8L00G63td7eovx75VfFB7JYqIILsmYXiXRDcwphpRkHhU%2FlQMSq0sGMa8fBCg1RkwE43gk50cJti7DcR98ZgYk5L%2FpoDx4EHUoC4GchNrtVA%3D%3D&commonAuthCallerPath=%2Fsamlsso&forceAuth=false&passiveAuth=false&referer=cpms.crncc.nihr.ac.uk&tenantDomain=carbon.super&sessionDataKey=17b5e51b-ac59-4954-88ea-a89c8964cfbf&relyingParty=cpms.nihr.ac.uk&type=samlsso&sp=CPMS&isSaaSApp=false&authenticators=GoogleOIDCAuthenticator%3AGoogle%3BAttributeBasedAuthenticator%3ALOCAL). Completion of the SoECAT is mandatory for studies eligible for the NIHR portfolio and the support this provides (including access to excess treatment cost payments). We strongly advise submitting your SoECAT at least 3 weeks before the grant submission deadline in order to have it authorised and returned back to you before you submit your application.

In order to create a SoECAT, you will need to create an account in and follow the steps in the [user guide](https://www.nihr.ac.uk/documents/getting-started-and-logging-in-to-cpms/11462). Once your account has been created and is active, you can proceed.

Further Guidance on how to complete your SoECAT form can be found within the online tool, as well as on the [Online SoECAT Guidance page](https://www.nihr.ac.uk/documents/online-soecat-guidance/30396)

Please note that completion of the **SoECAT may not be necessary** when applying for funding to support: overarching programmes with no specific research study protocol, infrastructure, fellowships, anything where the grant is to be used for direct employment of a member of staff or purchase of an asset, and data or diagnostic reviews where recruitment data is not collected. Such applications should provide rationale in the Finance Section - ‘Justification of Budget’ to explain why a SoECAT was not submitted in this instance.

**Please attach your SoECAT Funder Export here**

Mandatory

Please upload your completed (and approved) SoECAT Funder Export here.

Attach

**Please tick ALL the following that apply:**

***Please note that ‘sample’ can include, images, data and human tissue/fluid samples.***

* Select **'clinical trial'** if you will be evaluating the effectiveness and safety of new tests and treatments on recruited patients
* Select **'prospective sample collection'** if the proposed work will involve the collection of patient samples
* Select **'retrospective analysis of an existing collection of clinical samples'** if the proposed work involves 1) collection of existing patient samples 2) analysis of data originally collected for a different purpose e.g. in-depth analysis of trial databases, repositories of patient data, images and/or patient samples

**The proposed study is**

 **A clinical trial**

**A prospective sample collection**

**A retrospective analysis of an existing collection of clinical samples**

If ‘A clinical trial’ selected following question appears:

**Clinical Trial**

**Type of trial**

 **Observational study**

 **Treatment/intervention trial**

If ‘Treatment/intervention trial’ selected following question appears:

|  |
| --- |
| **Please specify the phase of the proposed clinical trial. e.g. Phase II, Phase III.** |
| Mandatory |

**Please upload a trial schema of the proposed study (single-side of A4).**

This should capture the study design, highlighting the flow and number of patients. Please include additional information such as eligibility, screening, randomisation and any subsequent activity through to follow-up. One page MS Word or PDF attachments only. Upload must not exceed 10MB in file size.

Attach

|  |
| --- |
| **Please clearly describe your power calculations and statistical analysis plan.**You should provide a clear justification for your power calculations, sample sizes, stratification factors, randomisation ratio etc. to provide the reviewer with sufficient reassurance that the study has been suitably powered. |
| Mandatory*max. 500 words* |

|  |
| --- |
| A picture containing porcelain  Description automatically generated**Please specify your chosen primary and secondary end points (including how they will be measured), along with any proposed interim analysis and early stopping rules.****Please specify your chosen primary and secondary end points (including how they will be measured), along with any proposed interim analysis and early stopping rules** What are you looking to measure in this study in order to address the research question? Please also detail the length of follow up required and the proposed early stopping criteria, and whether you intend to conduct any interim analyses during the study. |
| Mandatory*max. 300 words* |

|  |
| --- |
| **What will be your inclusion and exclusion criteria for recruiting patients?** |
| Mandatory*max. 300 words* |

|  |
| --- |
| **Patient Recruitment Strategy**What is your planned recruitment strategy? Do you have any pilot data to demonstrate feasibility of recruitment? How many centres will be involved and at what point will they be set up? What is your anticipated rate of recruitment/timescale for recruitment?What steps will you take to ensure the patient cohort is representative of the diversity seen in the UK population? **We know that prostate cancer disproportionately affects black men and so please also detail your strategy to** **recruit black men** **specifically**.If patient samples are to be collected, what type of tissue will be obtained and how many samples will be required? |
| Mandatory*max. 750 words* |

|  |
| --- |
| **Recruitment contingency**What are the likely challenges with patient recruitment/retention? Have any allowances been made for patient drop out and/or slower rate of recruitment? What steps will you take to mitigate the risk of not recruiting a sufficient number of patients and ensure appropriate strategies for retention? |
| Mandatory*max. 500 words* |

|  |
| --- |
| **What is your experience of delivering studies in a clinical setting?**Please specify your experience of delivering studies of this nature. |
| Mandatory*max. 200 words* |

|  |
| --- |
| **What are the arrangements for the support, management and oversight of the trial?**We want to know what existing infrastructure you have or will have in place to support clinical trials at the institutions involved (e.g. a dedicated Clinical Trials Unit, nursing support, data management and data analyst support). We also want to know whether there are appropriate governance arrangements in place to ensure expert advice and monitoring that is independent of the trial team (e.g. a Trial Steering Committee and Independent Data Monitoring Committee). Note, where a Trial Steering Committee is in place, we expect to have observer status and reserve the right to attend the meetings. |
| Mandatory*max. 500 words* |

|  |
| --- |
| A picture containing porcelain  Description automatically generated**Please detail what would be expected of a patient enrolled to this study?****Please detail what would be expected of a patient enrolled to this study?**Careful consideration from the patient perspective as to the expectations of the trial participants will help facilitate recruitment to your study (as a trial that is considered unacceptable to the majority of patients will struggle to recruit sufficient numbers).Please therefore describe the level of commitment, number of visits etc. expected of those recruited to the study, and how you have considered the trial protocol to ensure that it will be acceptable and sensitive to the situations of potential research participants.This question will be considered by our Patient & Public Involvement Representatives, so please think carefully about the impact on the patient. |
| Mandatory*max. 300 words* |

**Insert Patient flow chart (optional)**

One page MS Word or PDF attachments only. Upload must not exceed 10MB in file size.
Attach

**Prospective Sample Collection**

For applications looking to obtain new samples **(where ‘samples’ can include images and human tissue/fluid samples).**

\*\*Please ensure that you have considered the ethical implications associated with sample collections. Further details will be requested in the *‘Approvals and Licences’* section.\*\*

|  |
| --- |
| **Please provide details on how the samples and/or data will be acquired including the type of material that will be obtained and how many samples will be required.**Will the samples be obtained from existing infrastructure and if so, has that access been approved? Have you considered existing sample repositories? We want to know why there is a need for this prospective collection and whether the number and quality of samples is suitable and fit for purpose. |
| Mandatory*max. 500 words* |

|  |
| --- |
| **Please detail how the samples and/or data will be appropriately stored and managed.**We’re looking for information on how the samples and/or data will be stored and made available to appropriate researchers. If necessary, do you have the required approvals? |
| Mandatory*max. 300 words* |
|  |
| **What measures will be in place to allow the samples/data to be accessible as an open resource for future work?**We’re looking for information on whether (and how) the samples will be made available for other researchers to access in the future. |
| Mandatory*max. 300 words* |

**Retrospective analysis of an existing collection of clinical samples**

|  |
| --- |
| **Where will the proposed samples and/or data come from? What are the practical considerations in order to access the relevant samples/data?**We want to know which clinical trial/repository you will be accessing the proposed data/samples from, and whether the relevant parties have agreed and/or you have approved access to this resource. We’d like to know how you will access the samples/data/images required for your proposal and whether there are any logistical considerations to be aware of. *It is our expectation that all approvals or agreements in principle from all relevant parties are in place at the point of submission of your application. If you have been granted approval from the relevant parties of the original trial/biobank, to access the samples/data you’re intending to use, please upload a letter of support from the relevant parties here as confirmation. However, if you have yet to obtain approval, please state why this has not yet been obtained.* |
| Mandatory*max. 500 words* |

**Approvals letter of support (optional)**Attach

|  |
| --- |
| **What added value would the proposed research provide, over and above that of the original trial and/or other published data?**We want to know why your proposed research is important and what new knowledge would be generated that builds upon the findings of the original trial and/or any other published data in the area of your proposal. You should also explain why such a proposal is needed now and how it will differ from or complement any other planned, ongoing, or recently completed studies. |
| Mandatory*max. 300 words* |

|  |
| --- |
| **Patient & Public Involvement** |

**It is in your interest to take a great deal of care over this section.**

Our Patient and Public Involvement (PPI) representatives will read and assess only the information you provide in the lay summary, patient and public involvement and clinical research sections.

Please describe how men with prostate cancer, or their relatives/partners etc., have and/or will be involved in the design, planning and management of this research, and what their specific role will be.

Prostate Cancer UK supports the active involvement of patients and the public in research activities enabling high quality patient focused research. Involving people affected by prostate cancer throughout all stages of your research will likely lead to better quality funding applications and improved outcomes of research, thus resulting in applications that are more likely to be successful.

Tips for including PPI in your research:

* You can use our [Patient Representative Network](https://prostatecanceruk.org/research/for-researchers/involvement) to discuss your proposed research question(s) with people affected by prostate cancer to ask whether your planned research is relevant to them, and how they might be involved throughout your project.
* Refer to [NIHR involve PPI guidelines](https://www.nihr.ac.uk/documents/ppi-patient-and-public-involvement-resources-for-applicants-to-nihr-research-programmes/23437) for good PPI practice.

Any PPI described in the questions below **must be relevant** and **specific** to the studies outlined in this application.

|  |
| --- |
| **How have you involved men with prostate cancer, or their relatives/partners etc., to date in the development and planning of this proposal?**You may wish to include who you have involved, their role, the impact of their involvement etc.  |
| Mandatory*max. 300 words* |

|  |
| --- |
| **How will men with prostate cancer, or their relatives/partners etc., be involved in the delivery and management of this research, if funded?**You may wish to include who you plan to involve; how they will be involved/what their role will be; what impact you hope their involvement will bring etc. |
| Mandatory*max. 300 words* |

|  |
| --- |
| **How do you plan to engage with the wider community and disseminate your research findings to people affected by prostate cancer?**It is expected that research directly involving men affected by prostate cancer has a clear plan for feeding back results to participants at the end of the study, as well as more widely to the general public. |
| Mandatory*max. 400 words* |

|  |
| --- |
| **Outputs and Impact** |

|  |
| --- |
| **Dissemination & Data Sharing**A picture containing porcelain  Description automatically generated**Dissemination and Data Sharing**Describe how you intend to disseminate the outcomes of your research to the prostate cancer research community, during and at the end of the study. Please also describe how you will make any data, cell lines, tissue samples, excess material etc. freely available to others in the academic community. |
| Mandatory*max. 300 words* |

|  |
| --- |
| **What will be the potential impact of your research (both in the short and long term)? How will this research make a transformational impact?**A picture containing porcelain  Description automatically generated**What will be the potential impact of your research (both in the short and long term)? How will this research make a transformational impact?**We wish to understand the potential impact of your research both in the short and longer term, and how this study could make a transformational impact.  Our ultimate aim is to deliver clinical impact as quickly as possible to improve the lives of men affected by, or at high risk of, prostate cancer. Proposals should consider how we may accelerate the realisation of this clinical impact, for instance by delivering a transformational step change in our understanding of the disease; by directly delivering evidence that leads to practice change and patient benefit; or by significantly accelerating the progression towards that patient benefit. Your response should focus on the impact to these men rather than just purely academic outputs. |
| Mandatory*max. 500 words* |

|  |
| --- |
| **What would need to happen after this grant (if successful) to realise the long term impact for men described above?** A picture containing porcelain  Description automatically generated**What would need to happen after this grant (if successful) to realise the long term impact for men?**We wish to understand how your research fits into the wider research landscape and the potential impact of your work across a timescale longer than this grant to assess your plans for achieving impact.Please provide brief details of any subsequent steps/follow-on funding that will be required to realise the clinical impact and how you intend to fund them (including proposed funders/funding schemes, commercial partners/licencing etc.). |
| Mandatory*max. 500 words* |

|  |
| --- |
| **Lay Summary** |

**Guidance**

Please ensure this summary does not contain any information that is commercially sensitive, or likely to be considered as such in the future, as this lay summary may be used by Prostate Cancer UK to publicise our research portfolio should your application be successful in receiving funding.

**It is in your interest to take a great deal of care over this section.**

The assessment of our Patient and Public Involvement (PPI) representatives will primarily be based upon the information you provide in the lay summary, patient and public involvement and clinical research sections.

Describe the research proposal under the provided headings, in terms understandable to a reader with no specialist scientific or medical knowledge. This section should make complete sense when read in isolation to the rest of your application so don’t refer to any references, diagrams or acronyms included elsewhere in your proposal.

Tips for writing a lay summary:

* Pitch the summary at a level similar to that of a medical research report in a newspaper.
* Ask someone without a scientific background to read the summary before submitting your application.
* Do not include scientific jargon or abbreviations without further explanation.

Further guidelines for the involvement of patients in your research and how our Patient Representative Network could strengthen your application can be found on our website.

Prostate Cancer UK staff will take no responsibility for translating the science if the lay summary is inadequate. If your lay summary is not clear then the reviewer may not be able to see the importance of your research project for men affected by prostate cancer, and you may fail to secure funding as a direct result.

|  |  |
| --- | --- |
| **Lay title** | *max. 150 words* |

|  |
| --- |
| **What are you proposing?** |
| Mandatory*max. 200 words* |

|  |
| --- |
| **Why are you proposing it?** |
| Mandatory*max. 200 words* |

|  |
| --- |
| **How are you proposing to do it?** |
| Mandatory*max. 200 words* |

|  |
| --- |
| **What evidence or supporting data do you have to support your proposal?** |
| Mandatory*max. 200 words* |

|  |
| --- |
| **What are the expected, short term outcomes of this study?**What are you expecting to achieve by the end of the grant and what will need to happen next in order to realise the potential benefit to those living with, or at risk of, prostate cancer. |
| Mandatory*max. 200 words* |

|  |
| --- |
| **What do you foresee the eventual clinical impact of this study to be?**How could your research make a difference to the lives of those affected by prostate cancer? How do you envision your research impacting clinical practice and the way that men are diagnosed and/or treated? Over what time frame do you believe this impact could be realised?  |
| Mandatory*max. 200 words* |

|  |
| --- |
| **References** |

|  |
| --- |
| **Include up to 200 full references (in Vancouver format)** A picture containing porcelain  Description automatically generated**References**Examples of Vancouver formatted references: Endres M, Engelhardt B, Koistinaho J, Lindvall O, Meairs S, Mohr JP, et al. Improving outcome after stroke: Overcoming the translational roadblock. Cerebrovasc Dis. 2008, Feb, 22;25(3):268-78. Fanta CH. Asthma. N Engl J Med. [Internet] 2009 [cited 2013 Jan 9]; 360(10):1002-14. Available from: doi: 10.1056/NEJMra0804579 Foley KM, Gelband H, editors. Improving palliative care for cancer [Internet]. Washington: National Academy Press; 2001 [cited 2002 Jul 9]. Available from: https://www.nap.edu/catalog/10149/improving-palliative-care-for-cancer  Harnden P, Joffe JK, Jones WG, editors. Germ cell tumours V. Proceedings of the 5th Germ Cell Tumour Conference; 2001 Sep 13-15; Leeds, UK. New York: Springer; 2002.  |
| Mandatory*max. 5000 words* |

|  |
| --- |
| **Gantt Chart** |

Insert a Gantt chart detailing the main goals, milestones and key deliverables of your proposed study. This should be broken down into the corresponding work-packages where appropriate and should detail the management and staffing resource for each component of the proposal.

These will be the key goals and timelines from which the progress of your research shall be measured against, so please ensure that they are achievable within the requested timeframe.

**MS Word or PDF attachments only**. Upload must not exceed 10MB in file size.

Mandatory

Attach

|  |
| --- |
| **Approvals and Licences** |

**Approvals and licences**

All necessary regulatory approvals and licences for the proposal must be in place before the corresponding work can commence. In most instances, approvals and licences should be in place before the grant begins, and so should not be included within the study schedule/Gantt chart. We appreciate that some proposals may not require specific approvals until the later years of the study (e.g. where a clinical trial is not scheduled until after some initial pre-clinical studies). In this instance, it is permissible for the approvals to be obtained at the relevant time; however, this must be approved by Prostate Cancer UK in advance of the grant commencing.

Funding will not be released until all necessary approvals and licences are in place (unless specifically agreed in advance with Prostate Cancer UK, in which case, payments may be withheld during the grant until the necessary approvals are in place).

**Ethical Approval**

Please specify whether your research will involve the use of human subjects or patient samples, and whether ethical approval is required.

The UKCRC Tissue Directory and Coordination Centre supports the work of biobanks by improving access to their human tissue samples for research purposes. The Tissue Directory aims to maximise the use of new and existing human tissue sample collections and allows searching based on various criteria and available datasets. For further advice and guidance please refer to the [UK Clinical Research Collaboration website](https://biobankinguk.org/).

|  |
| --- |
| **Does this research involve the use of human subjects or tissue?** |
| Select YES or NOMandatory |

If ‘Yes’ selected following question appears:

|  |
| --- |
| **Is ethical approval required?** |
| Select YES or NOMandatory |

If ‘Yes’ selected following question appears:

|  |
| --- |
| **Has ethical approval been obtained?** |
| Select YES or NOMandatory |

If ‘Yes’ selected following appears:

**Please insert a scanned copy of the letter here.**

Please note - only word or pdf documents can be attached

Attach

If ‘No’ selected for ‘Has ethical approval been obtained?’ following appears:

|  |
| --- |
| **Please provide further details if ethical approval has yet to be obtained** |
| Mandatory*max. 1000 words* |

**Use of Animals**

**Use of Animals**If you are proposing the use of animals in your research, you must detail the number and species of animal to be used and whether the animals will be genetically modified. You must clearly justify why an animal model is necessary to advance this research. In particular, taking into careful consideration:

* whether the research question can be addressed via other means, without the use of animals
* whether the potential benefit justifies the possible adverse effects to the animals
* why the specific approach/model is the most appropriate
* how to optimise the experimental design to minimise the number of animals required
* what steps will be taken to minimise any pain, suffering, distress and lasting harm to the animals
* how the results and resources can be shared with the research community

You should also consider whether anyone else has already generated the model(s) required for this study and if so, why it is not feasible to obtain the necessary materials from them and/or why new models need to be generated.

Please also describe how the proposed sample size has been determined and how the project plan has been refined to adhere to the 3Rs by using the minimum number of animals possible and causing the least suffering, whilst also ensuring that the study is sufficiently powered and reproducible (please refer to <https://www.nc3rs.org.uk/> for further details). The NC3Rs offer a free online tool, the [Experimental Design Assistant](https://eda.nc3rs.org.uk/) (EDA), providing guidance on experimental design for researchers. The tool helps to ensure that researchers use the minimum number of animals required to achieve the scientific objectives, as well as the most appropriate methods to reduce subjective bias and to optimise the statistical analysis. For further advice and guidance please refer to <https://www.nc3rs.org.uk/>.

We require this information to ensure that all necessary approvals are/will be in place and to collect data for the Association of Medical Research Charities (AMRC) on the use of animals within our grant portfolio. If the appropriate approvals are already in place, please provide the Home Office Number and upload the licence in the corresponding section within the form (MS Word or PDF only).

|  |
| --- |
| **Does this proposal involve the use of animals?** |
| Select YES or NOMandatory |

If ‘Yes’ selected following questions appear:

|  |
| --- |
| **Which animal species will be used?**Please detail all species which are to be used, including those not protected under UK law. If more than one species of animal is to be used, please enter these separately (separated by a comma). |
| Mandatory |

|  |
| --- |
| **How many animals will be used?**A picture containing porcelain  Description automatically generated**How many animals will be used?**The number of animals used must be fully justifiable and should be the minimum number required in order to answer the research question(s).  Experimental design and breeding schedules should be carefully thought through so that they are as efficient as possible in order to minimise the number of animals required. |
| Mandatory |

|  |
| --- |
| **Will any of these animals be genetically modified?**A picture containing porcelain  Description automatically generated**Will any of these animals be genetically modified?**We require this information in order to collect data for the Association of Medical Research Charities (AMRC) on the use of animals within our grant portfolio. |
| Select YES or NOMandatory |

|  |
| --- |
| **Please explain briefly why non-animal alternatives are not suitable and how the project adheres to the principles of the 3Rs.**The principles of the 3Rs were developed to create a framework to ensure a more humane use of animals in research. The 3Rs stand for:**Replacement** - Using alternative approaches that avoids or minimises the use of animals**Reduction**  - Careful planning and study design to minimise the number of animals needed**Refinement** - Optimisation of approach to minimise animal suffering and improve welfare All steps should be taken to minimise any pain, suffering, distress and lasting harm arising from the scientific procedures, housing and husbandry. High standards of animal welfare must be maintained throughout the life of the animals.Careful consideration should be given to the fate of the animals, in particular identifying humane endpoints where the experiments have the potential to cause harm to animals.  The use of humane endpoints should be monitored throughout the experiments and continually reviewed and refined as required based on experience.Any opportunities to share data and resources (including models, tissue and blood etc.) should be explored. |
| Mandatory*max. 200 words* |

|  |
| --- |
| **How has the proposed sample size been determined?**Please indicate how the number of animals has been determined in order to minimise the number of animals needed, whilst also ensuring that the study is sufficiently powered and reproducible.A picture containing porcelain  Description automatically generated**How has the proposed sample size been determined?**The number of animals required must be clearly justified and supported by sample size calculations where appropriate, taking into consideration the planned statistical analyses, the significance threshold and power level, the population variance etc. |
| Mandatory*max. 300 words* |

|  |
| --- |
| **Have others already generated the proposed model(s) required for this study?**If so, why do you need to generate new models and have you approached the relevant people regarding a potential collaboration to obtain the necessary materials? |
| Mandatory*max. 300 words* |

|  |
| --- |
| **Have the necessary animal licences/approvals been obtained?** |
| Select YES or NOMandatory |

If ‘Yes’ selected following question appears:

**Home Office License**

Please provide the home office licence no(s) here.

Add Home office license…

**Pop up window:**

Mandatory

**Add Home office license number**

**Home office license number**

**Please attach your animal licence here**

Please note - we’re looking for evidence that approval has been granted, we therefore only require the title/approval page(s) to be uploaded, not the entire document. Only word or pdf documents can be attached.

Mandatory

Add..

If ‘No’ selected for ‘Have the necessary animal licences/approvals been obtained?’ following appears:

|  |
| --- |
| **Please provide further details if the necessary licences/approvals have yet to be obtained** |
| Mandatory*max. 200 words* |

**Use of Stem Cells**

Please indicate whether the research will involve the use of stem cells, providing further justification if embryonic stem cells are to be used.

|  |
| --- |
| **Does the proposed research involve the use of stem cells?** |
| (Select) No stem cells being use or Cancer stem cells only or Embryonic stem cells only or Both cancer & embryonic stem cellsMandatory |

If ‘Embryonic stem cells only’ OR ‘Both cancer & embryonic stem cells’ selected following question appears:

|  |
| --- |
| **Please justify why embryonic stem cells are required** |
| Mandatory*max. 200 words* |

|  |
| --- |
| **Intellectual Property / Scientific Integrity** |

**Technology Transfer Office**

|  |
| --- |
| **Please detail your institution’s current processes and available expertise in managing IP, including contact details of your IP/Tech Transfer Office**Please note, it is our expectation that any Foreground IP arising from Prostate Cancer UK funded research should be owned by and vest in the Research Institution, and that any net revenue generated from its commercial exploitation shall be shared in accordance with our [terms and conditions](https://prostatecanceruk.org/media/zrphpuk0/prostate-cancer-uk-terms-and-conditions-2019-v9-final.pdf). (up to 500 words). A picture containing porcelain  Description automatically generated**Please detail your institution’s current processes and available expertise in managing IP**We strongly recommend discussing this proposal with your IP/Technology Transfer Office and to complete this section with their support. Please provide the contact details of your colleague within your IP/Technology Transfer Office.   |
| Mandatory*max. 500 words* |

**Intellectual Property**

As stipulated in our [terms and conditions](https://prostatecanceruk.org/media/zrphpuk0/prostate-cancer-uk-terms-and-conditions-2019-v9-final.pdf), we consider Intellectual Property (IP) to include:

all materials, patent rights, know-how, trade marks, service marks, registered designs, copyrights, database rights, design rights, confidential information, applications for any of the above, and any similar right recognised from time to time in any jurisdiction, together with all rights of action in relation to the infringement of any of the above.

We require all considerations surrounding IP to be declared and agreed upon upfront, before any award can commence. Any potential to develop new, FOREGROUND IP should be identified and detailed below, along with your proposed plans to suitably protect and utilise the IP. We expect to be consulted on the exploitation of any new FOREGROUND IP and for any profits from exploitation to be shared in accordance with our grant [terms and conditions](https://prostatecanceruk.org/media/zrphpuk0/prostate-cancer-uk-terms-and-conditions-2019-v9-final.pdf).

We also appreciate that your research might be building upon existing, BACKGROUND IP generated by either yourselves or others.  We therefore require that you declare all relevant Background IP specifically relating to this proposal, how this will be utilised in this project and whether your proposed study is likely to add significant commercial value to this existing IP.

**FOREGROUND IP**

**FOREGROUND IP**
Any new, Foreground Intellectual Property arising from a Prostate Cancer UK funded grant shall be owned by and vest in the host institution. The host institution should use reasonable endeavours to identify, protect and commercially exploit any Foreground IP arising from the study, and should promptly notify Prostate Cancer UK of any such IP as it arises.

If the host institution decides not to protect or to abandon any such IP generated through this research, then Prostate Cancer UK shall have the right, but not the duty, to protect and exploit the IP commercially.

Please refer to our [terms and conditions](https://prostatecanceruk.org/media/zrphpuk0/prostate-cancer-uk-terms-and-conditions-2019-v9-final.pdf) for further information.

|  |
| --- |
| **Do you expect any new Foreground IP to be generated as a result of this research?** |
| Select YES or NOMandatory |

If ‘Yes’ Selected box appears:

|  |
| --- |
| **Please provide further detail regarding the new IP you expect to generate**(up to 500 words) |
| Mandatory*max. 500 words* |

**BACKGROUND IP**

**BACKGROUND IP**
We recognise that your research may build upon or utilise pre-existing Background IP, generated and owned by yourselves or others. For this reason we want to be clear upfront regarding what existing Background IP is in place, and what new, Foreground IP may be generated through Prostate Cancer UK funded research.

Where Background IP has already been protected, we do not expect ownership of that IP to change.  However, if research funded by Prostate Cancer UK adds significant value to the Background IP that may strengthen its potential for commercialisation, its value at the point of commercialisation, or may provide opportunities for additional commercial exploitation, then we would expect to enter discussions with the relevant parties regarding a revenue share, royalty payments or other form of reimbursement to acknowledge the charity’s contribution towards the development of the resultant asset.

Please refer to our [terms and conditions](https://prostatecanceruk.org/media/zrphpuk0/prostate-cancer-uk-terms-and-conditions-2019-v9-final.pdf)terms and conditions for further information.

|  |
| --- |
| **Is this proposed research dependent upon any pre-existing, Background IP (owned by either yourselves or a third party/parties)?** |
| Select YES or NOMandatory |

If ‘Yes’ selected following question appears:

|  |
| --- |
| **Please list all relevant Background IP associated with this work**Please specify the owner of that IP, whether discussions have been held with them regarding access to this IP/provision of materials (e.g. provision of drug, biomarker etc.) and whether any agreements are already in place covering the potential future exploitation of this Background IP (up to 500 words) |
| Mandatory*max. 500 words* |

 **Optional supporting letter(s)**

If possible, it will strengthen your proposal if you can provide a letter of support from any third party/parties whose Background IP shall be utilised with this proposed study. Upload all letters as a single Word or PDF only.

Attach

|  |
| --- |
| **As a result of this proposed research, will significant commercial value be added to the Background IP? If so, please provide further details**(up to 500 words) |
| Mandatory*max. 500 words* |

**IP Commercialisation**

**IP Commercialisation**
Prostate Cancer UK requires any intellectual property generated to be properly identified, secured and exploited.  Where Prostate Cancer UK funds have supported the generation of Foreground IP, or added significant value to pre-existing Background IP, and that IP is subsequently commercially exploited, then our contribution towards the discovery and/or development of this IP should be recognised through a revenue share, royalty payments or another form of reimbursement to enable the charity to continue to pursue its charitable objectives.

Please refer to our [terms and conditions](https://prostatecanceruk.org/media/zrphpuk0/prostate-cancer-uk-terms-and-conditions-2019-v9-final.pdf) for further details.

|  |
| --- |
| **Have you, or do you expect to, enter into any commercialisation agreements with a third party(ies) as a result of the work proposed in this application? If so, please provide further details** Where significant value is likely to be added to a commercial asset as a result of Prostate Cancer UK funding, please explain the proposed arrangements for revenue sharing, royalty payments or other reimbursement from the party commercialising the asset to your host institution / to Prostate Cancer UK. (up to 500 words) |
| Mandatory*max. 500 words* |

|  |
| --- |
| **Finances** |

**Itemised Budget**

**Please refer to our**[**Finance Guidance**](https://prostatecanceruk.org/research/for-researchers/our-funding-process-and-how-to-apply/finance-guidance)**for further details regarding cost eligibility.**

Your budget**MUST**be broken down in as much detail as possible and entered as separate items under the relevant headings below.  Any items which appear excessive or which have not been suitably justified will be queried by Prostate Cancer UK staff and may be removed from the budget if the application is recommended for funding.

Please note that applications should be costed in line with the [AcoRD framework](https://www.gov.uk/government/publications/guidance-on-attributing-the-costs-of-health-and-social-care-research) for attributing the costs of clinical research, and our standard terms and conditions regarding eligibility of certain costs apply. Those applications with a clinical element must complete a Schedule of Events Cost Attribution Tool (SoECAT) as outlined in the Clinical Research section earlier in these guidelines.

**Salary Costs**No Salary Costs have been entered

Add Salary Costs

**Pop-up window:**

**Staff Member**

|  |
| --- |
| Staff Name (Please enter “Unknown” if not known at time of application.) |
|  |

|  |
| --- |
| Type |
| Select one: Clinical research training fellow, Loss of earnings, PhD Student, Post-doctoral researcher, Principal Investigator, Research assistant, Research fellow, Research nurse, Scientific officer, Statistician, Technician, Other |

|  |
| --- |
| Increment Date |
|  |

|  |
| --- |
| Starting Scale And Grade |
|  |

|  |
| --- |
| Inflation Rate (%) |
|  |

|  |
| --- |
| % FTE |
|  |

**Allowances**

Number of ‘Years’ column shown based on duration entered in ‘Project Summary’ section

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Description** | **Year 1 (£)** | **Year 2 (£)**  | **Year 3 (£)**  | **Total Cost (£)** |
| Basic Salary |  |  |  | *Auto-calculated* |
| Employer Contributions |  |  |  | *Auto-calculated* |
| London allowance |  |  |  | *Auto-calculated* |
| **Total** | *Auto-calculated* | *Auto-calculated* | *Auto-calculated* | *Auto-calculated* |

Once completed following table shows:

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Staff Type** | **Name** | **Year 1 (£)** | **Year 2 (£)** | **Year 3 (£)** | **Overall (£)** |  |
| *Pulled from pop up window* | *Pulled from pop up window* | *Pulled from pop up window* | *Pulled from pop up window* | *Pulled from pop up window* | *Auto-calculated* | Edit…Delete… |
|  |  | *Auto-calculated* | *Auto-calculated* | *Auto-calculated* | *Auto-calculated* |  |

**Research Expenses**No Research Expenses have been entered

Add Research Expenses

**Pop-up window:**

**Research Expenses...**

|  |
| --- |
| Item |
|  |

 **Allowances**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Total Costs (£)** | **Year 1** | **Year 2** | **Year 3** | **Total** |
|  |  |  |  | *Auto-calculated* |

Once completed following table shows:

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Research Expenses** | **Year 1 (£)** | **Year 2 (£)** | **Year 3 (£)** | **Overall (£)** |  |
| *Pulled from pop up window* | *Pulled from pop up window* | *Pulled from pop up window* | *Pulled from pop up window* | *Auto-calculated* | Edit…Delete… |
|  | *Auto-calculated* | *Auto-calculated* | *Auto-calculated* | *Auto-calculated* |  |

**Animal Purchase Costs**No Animal Purchase Costs have been entered

Add Animal Purchase Costs

**Pop-up window:**

**Animal Purchase Costs...**

|  |
| --- |
| Species |
|  |

|  |
| --- |
| Total Number of Animals |
|  |

**Allowances**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Total Costs (£)** | **Year 1** | **Year 2** | **Year 3** | **Total** |
|  |  |  |  | *Auto-calculated* |

Once completed following table shows:

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Item** | **Number of Animals** | **Year 1 (£)** | **Year 2 (£)** | **Year 3 (£)** | **Overall (£)** |  |
| *Pulled from pop up window* | *Pulled from pop up window* | *Pulled from pop up window* | *Pulled from pop up window* | *Pulled from pop up window* | *Auto-calculated* | Edit…Delete… |
|  |  | *Auto-calculated* | *Auto-calculated* | *Auto-calculated* | *Auto-calculated* |  |

**Animal Maintenance Costs**No Animal Maintenance Costs have been entered

Add Animal Maintenance Costs

**Pop-up window:**

**Animal Maintenance Costs...**

|  |
| --- |
| Species |
|  |

**Allowances**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Total Costs (£)** | **Year 1** | **Year 2** | **Year 3** | **Total** |
|  |  |  |  | *Auto-calculated* |

Once completed following table shows:

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Species** | **Year 1 (£)** | **Year 2 (£)** | **Year 3 (£)** | **Overall (£)** |  |
| *Pulled from pop up window* | *Pulled from pop up window* | *Pulled from pop up window* | *Pulled from pop up window* | *Auto-calculated* | Edit…Delete… |
|  | *Auto-calculated* | *Auto-calculated* | *Auto-calculated* | *Auto-calculated* |  |

**Other Costs**No Other Costs have been entered

Add Other Costs

**Pop-up window:**

**Other Costs...**

|  |
| --- |
| Item |
|  |

**Allowances**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Total Costs (£)** | **Year 1** | **Year 2** | **Year 3** | **Total** |
|  |  |  |  | *Auto-calculated* |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Totals** | **Year 1 (£)** | **Year 2 (£)** | **Year 3 (£)** | **Overall (£)** |
| Salaries |  |  |  | *Auto-calculated* |
| Research Expenses |  |  |  | *Auto-calculated* |
| Animal PurchaseCosts |  |  |  | *Auto-calculated* |
| AnimalMaintenance Costs |  |  |  | *Auto-calculated* |
| Other Costs |  |  |  | *Auto-calculated* |
| **Totals** | *Auto-calculated* | *Auto-calculated* | *Auto-calculated* | *Auto-calculated* |

|  |
| --- |
| **Justification of Budget****A picture containing porcelain  Description automatically generated****Justification of Budget**Please provide a brief justification of the costs that you expect to incur (in no more than 500 words).  In particular you should justify the number and seniority of any staff to be employed on the project, and the inclusion of any costly equipment (or any other significant expenditure) deemed essential for the proposed research. If the proposal includes a clinical element, please also state whether the study is likely to receive support from a research network and, if so, the support that will be provided.   |
| Mandatory*max. 750 words* |

|  |
| --- |
| **Will additional funding be required (or has additional funds already been secured) from third parties to support delivery of this study?** If the amount requested in this submission does not cover the full amount of direct research costs for the study, please provide details as to how the remaining costs will be met. For example, will the study be delivered in collaboration with an industry partner, will funds be partly covered through existing grant/institutional funding, does the additional funding still need to be secured etc. |
| MandatoryMax. 500 words |

|  |
| --- |
| **What upfront leveraged support might be available from other sources were this proposal to be funded and what is your strategy for gaining further additional leveraged support during the lifetime of the grant?** **A picture containing porcelain  Description automatically generated**Proposals which can demonstrate additional leveraged support from the host institution and/or from collaborating partners will be looked upon favourably. Applicants should therefore consider what upfront leveraged support might be available from other sources to provide added benefit to the focus of this proposal, as well as what their strategy will be for gaining further additional leveraged support if this application was successful.Prostate Cancer UK will be discussing this call with other funders, donors and partners to maximise our funding through this initiative; However, we expect that the greatest likelihood of success in engaging other partners (particularly with pharmaceutical companies) will require applicants to make those approaches and engage directly. Therefore, where applicable proposals should outline how the applicants have engaged with, or how they propose to engage with, other parties to capitalise on this grant to leverage additional complementary funding.  |
| MandatoryMax. 500 words |

|  |
| --- |
| **Declarations- Candidate** |

**Candidate**

|  |  |
| --- | --- |
| **Title**  | *Auto-populated* |
| **Forename(s)**  | *Auto-populated* |
| **Surname**  | *Auto-populated* |

**Other sources of funding**

Please can you clarify whether you have applied elsewhere for funding on the topic of this application. It is acceptable to have submitted the same proposal (or elements of it) to another funder, however, please give an indication as to when you will know the outcome of the other submission(s). You must inform the charity of the outcome as soon as it is known, and if you are successful in receiving funding for your research then we will need to ensure that there is no duplication of funding for the same study.

|  |
| --- |
| **Are you awaiting the outcome of any other funding applications?**  |
| Select YES or NO Mandatory |

If ‘Yes’ selected following question appears:

|  |
| --- |
| **Please give funding body, grant title, budget, and comment on the overlap with this proposal.**  |
| Mandatory    *max. 200 words*  |

|  |
| --- |
| **Where did you hear about this funding opportunity?** |
| Mandatory*max. 50 words* |

**Terms and Conditions**

Please use this link to view the Prostate Cancer UK [Terms and Conditions](https://prostatecanceruk.org/media/zrphpuk0/prostate-cancer-uk-terms-and-conditions-2019-v9-final.pdf).

*\*these terms are subject to change.*

|  |
| --- |
| **Candidate Declaration** |
| I have read the Prostate Cancer UK [Terms and conditions](https://prostatecanceruk.org/media/zrphpuk0/prostate-cancer-uk-terms-and-conditions-2019-v9-final.pdf) and agree to abide by them if funding is awarded. To the best of my knowledge, all the information given on this form is accurate. |

|  |  |
| --- | --- |
| **Candidate Acceptance** | *Tick box to accept* Mandatory |

**ORCiD account Declaration**

I confirm that the information on the ORCID accounts for the Lead and Joint-Lead Applicant(s) is accurate and up to date, and the information is publicly available as of the time of this submission.

|  |  |
| --- | --- |
| **ORCiD account confirmation** | *Tick box to accept* Mandatory |

|  |
| --- |
| **Declarations- Head of Department** |

|  |
| --- |
| **Head of Department**Please note – If the Head of Department is the Lead or Joint-Lead Applicant , a suitable deputy, with sufficient authority to approve, must be assigned to complete the approvals. |
| Add ContactMandatory |

Once contact added:

|  |  |  |  |
| --- | --- | --- | --- |
|  **Name**  | **Organisation** | **Status** |  |
| *Auto-populated* | *Auto-populated* | Unconfirmed | Remove |

|  |
| --- |
| **Please detail how you will support the Applicant Team**Please detail the host institution's commitment towards the proposed research; provide details of any extra support that is being provided/may be available to the applicants were this application to be successful, as well as the institution’s training and mentorship support for the experienced Early Career Researcher on the proposal, as well as any other early career researchers who will be involved in the delivery of the research. |
| Mandatory*max. 300 words* |

**Anti-Bullying Policy**

Grants will only be awarded to institutions that have official policies and procedures in place to appropriately handle instances of bullying.

|  |
| --- |
| **Does your institution have an anti-bullying policy?** |
| Select YES or NOMandatory |

If ‘Yes’ selected following question appears:

|  |
| --- |
| **Please provide a link to the policy here. Please ensure that the link can be accessed by those outside of your host institution. If no link is available please provide a brief description of your anti-bullying policy.** |
| Mandatory*max. 1000 words* |

**Scientific Integrity**

Grants will only be awarded to institutions that have official policy and procedures designed to protect scientific integrity.

|  |
| --- |
| **Does the host institution have official procedures in place to deal with suspected scientific fraud?** |
| Select YES or NOMandatory |

|  |
| --- |
| **Please elaborate on your scientific integrity policy here, either by providing a link or giving a brief description of the policy. Please ensure that the link can be accessed by those outside of your host institution.** |
| Mandatory*max. 1000 words* |

**Terms and Conditions**

Please use this link to view the Prostate Cancer UK [Terms and Conditions](https://prostatecanceruk.org/media/zrphpuk0/prostate-cancer-uk-terms-and-conditions-2019-v9-final.pdf).

*\*these terms are subject to change.*

|  |
| --- |
| **Head of Department Declaration** |
| As Head of Department, by ’ticking’ this box I am confirming that I have read this application and the accompanying [terms and conditions](https://prostatecanceruk.org/media/zrphpuk0/prostate-cancer-uk-terms-and-conditions-2019-v9-final.pdf) and that, if granted, the work will be accommodated and administered in the Department/Institution according to the regulations laid down by Prostate Cancer UK. All the necessary licences/approvals have been or are being sought. |

|  |  |
| --- | --- |
| **Head of Department Acceptance** | *Tick box to accept*Mandatory |

|  |
| --- |
| **Declarations- Finance Officer** |

|  |
| --- |
| **Finance Officer** |
| Add ContactMandatory |

Once contact added:

|  |  |  |  |
| --- | --- | --- | --- |
|  **Name**  | **Organisation** | **Status** |  |
| *Auto-populated* | *Auto-populated* | Unconfirmed | Remove |

**Terms and Conditions**

Please use this link to view the Prostate Cancer UK [Terms and Conditions](https://prostatecanceruk.org/media/zrphpuk0/prostate-cancer-uk-terms-and-conditions-2019-v9-final.pdf).

*\*These terms are subject to change.*

|  |
| --- |
| **Finance Officer declaration** |
| As Finance Officer, by 'ticking’ this box I am confirming that the institution will administer any grant awarded and will ensure the funds are used for the purpose for which they have been given.I confirm that I have read this application and acknowledge the accompanying terms and conditions of award, and if granted, the work will be carried out in accordance to these [terms and conditions](https://prostatecanceruk.org/media/zrphpuk0/prostate-cancer-uk-terms-and-conditions-2019-v9-final.pdf) as set out by Prostate Cancer UK. |

|  |  |
| --- | --- |
| **Finance Officer Acceptance** | *Tick box to accept*Mandatory |

|  |
| --- |
| **Validation** |

Please ensure you have completed all questions prior to submission.

|  |
| --- |
| **CVs - Lead Applicant / Joint-Lead Applicants (PDF only)** |

**Education**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **From** | **To**  | **Qualification**  | **Subject**  | **Country**  | **Institution**  | **Class** | **Department** |
| *(Auto populated from the Joint applicant’s ‘Manage my details’ section)* | *(Auto populated….)* | *(Auto populated….)* | *(Auto populated….)* | *(Auto populated….)* | *(Auto populated….)* | *(Auto populated….)* | *(Auto populated….)* |

**Employment**

|  |  |  |  |
| --- | --- | --- | --- |
| **From** | **To**  | **Position** | **Organisation**  |
| *(Auto populated from the Joint applicant’s ‘Manage my details’ section)* | *(Auto populated….)* | *(Auto populated….)* | *(Auto populated….)* |

|  |
| --- |
| **Publications**  |
| *Pulls from ’Lead Applicant Details’ section OR ‘Applicant Roles & Other Personnel’ section for Joint-Lead Applicants* |

|  |
| --- |
| **Previous Grants**  |
| *Pulls from ’Lead Applicant Details’ section OR ‘Applicant Roles & Other Personnel’ section for Joint-Lead Applicants* |

**Narrative CV**

|  |
| --- |
| **How have you contributed to the generation of knowledge?** |
| *Pulls from ’Lead Applicant Details’ section OR ‘Applicant Roles & Other Personnel’ section for Joint-Lead Applicants* |

|  |
| --- |
| **How have you contributed to the development of others?**  |
| *Pulls from ’Lead Applicant Details’ section OR ‘Applicant Roles & Other Personnel’ section for Joint-Lead Applicants* |

|  |
| --- |
| **How have you contributed to the wider research community?** |
| *Pulls from ’Lead Applicant Details’ section OR ‘Applicant Roles & Other Personnel’ section for Joint-Lead Applicants* |

|  |
| --- |
| **How have you contributed towards broader society (in a research capacity)?** |
| *Pulls from ’Lead Applicant Details’ section OR ‘Applicant Roles & Other Personnel’ section for Joint-Lead Applicants* |